Search Results - "Calverley, Peter M"

Changes in Forced Expiratory Volume in 1 Second over Time in COPD by Vestbo, Jørgen, Edwards, Lisa D, Scanlon, Paul D, Yates, Julie C, Agusti, Alvar, Bakke, Per, Calverley, Peter M.A, Celli, Bartolome, Coxson, Harvey O, Crim, Courtney, Lomas, David A, MacNee, William, Miller, Bruce E, Silverman, Edwin K, Tal-Singer, Ruth, Wouters, Emiel, Rennard, Stephen I

“…In patients with chronic obstructive pulmonary disease (COPD), lung function decreases rapidly. Analysis of data from a large observational study of COPD…”
Get full text

Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials by Calverley, Peter MA, Prof, Rabe, Klaus F, Prof, Goehring, Udo-Michael, MD, Kristiansen, Søren, PhD, Fabbri, Leonardo M, Prof, Martinez, Fernando J, Prof

“…Summary Background The phosphodiesterase-4 inhibitor roflumilast can improve lung function and prevent exacerbations in certain patients with chronic…”
Get full text

Exacerbations of Chronic Obstructive Pulmonary Disease and Cardiac Events. A Post Hoc Cohort Analysis from the SUMMIT Randomized Clinical Trial by Kunisaki, Ken M, Dransfield, Mark T, Anderson, Julie A, Brook, Robert D, Calverley, Peter M A, Celli, Bartolome R, Crim, Courtney, Hartley, Benjamin F, Martinez, Fernando J, Newby, David E, Pragman, Alexa A, Vestbo, Jørgen, Yates, Julie C, Niewoehner, Dennis E

“…Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are common, associated with acute inflammation, and may increase subsequent…”
Get full text

Effect of Home Noninvasive Ventilation With Oxygen Therapy vs Oxygen Therapy Alone on Hospital Readmission or Death After an Acute COPD Exacerbation: A Randomized Clinical Trial by Murphy, Patrick B, Rehal, Sunita, Arbane, Gill, Bourke, Stephen, Calverley, Peter M. A, Crook, Angela M, Dowson, Lee, Duffy, Nicholas, Gibson, G. John, Hughes, Philip D, Hurst, John R, Lewis, Keir E, Mukherjee, Rahul, Nickol, Annabel, Oscroft, Nicholas, Patout, Maxime, Pepperell, Justin, Smith, Ian, Stradling, John R, Wedzicha, Jadwiga A, Polkey, Michael I, Elliott, Mark W, Hart, Nicholas

“…IMPORTANCE: Outcomes after exacerbations of chronic obstructive pulmonary disease (COPD) requiring acute noninvasive ventilation (NIV) are poor and there are…”
Get full text

Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial by Martinez, Fernando J, Prof, Calverley, Peter M A, Prof, Goehring, Udo-Michael, MD, Brose, Manja, MSc, Fabbri, Leonardo M, Prof, Rabe, Klaus F, Prof

“…Summary Background Roflumilast reduces exacerbations in patients with severe chronic obstructive pulmonary disease. Its effect in patients using fixed…”
Get full text

Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial by Vestbo, Jørgen, Prof, Anderson, Julie A, MA, Brook, Robert D, MD, Calverley, Peter M A, Prof, Celli, Bartolome R, MD, Crim, Courtney, MD, Martinez, Fernando, MD, Yates, Julie, BS, Newby, David E, Prof

“…Summary Background Chronic obstructive pulmonary disease (COPD) often coexists with cardiovascular disease. Treatments for airflow limitation might improve…”
Get full text

Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials by Fabbri, Leonardo M, Prof, Calverley, Peter MA, Prof, Izquierdo-Alonso, José Luis, MD, Bundschuh, Daniela S, PhD, Brose, Manja, MSc, Martinez, Fernando J, Prof, Rabe, Klaus F, Prof

“…Summary Background Patients with chronic obstructive pulmonary disease (COPD) have few options for treatment. The efficacy and safety of the…”
Get full text

Characterisation of COPD heterogeneity in the ECLIPSE cohort by Agusti, Alvar, Calverley, Peter M A, Celli, Bartolome, Coxson, Harvey O, Edwards, Lisa D, Lomas, David A, MacNee, William, Miller, Bruce E, Rennard, Steve, Silverman, Edwin K, Tal-Singer, Ruth, Wouters, Emiel, Yates, Julie C, Vestbo, Jørgen

“…Chronic obstructive pulmonary disease (COPD) is a complex condition with pulmonary and extra-pulmonary manifestations. This study describes the heterogeneity…”
Get full text

Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype by Agustí, Alvar, Edwards, Lisa D, Rennard, Stephen I, MacNee, William, Tal-Singer, Ruth, Miller, Bruce E, Vestbo, Jørgen, Lomas, David A, Calverley, Peter M A, Wouters, Emiel, Crim, Courtney, Yates, Julie C, Silverman, Edwin K, Coxson, Harvey O, Bakke, Per, Mayer, Ruth J, Celli, Bartolome

“…Because chronic obstructive pulmonary disease (COPD) is a heterogeneous condition, the identification of specific clinical phenotypes is key to developing more…”
Get full text

Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial by Watz, Henrik, Dr, Tetzlaff, Kay, Prof, Wouters, Emiel F M, Prof, Kirsten, Anne, MD, Magnussen, Helgo, Prof, Rodriguez-Roisin, Roberto, Prof, Vogelmeier, Claus, Prof, Fabbri, Leonardo M, Prof, Chanez, Pascal, Prof, Dahl, Ronald, Prof, Disse, Bernd, MD, Finnigan, Helen, MSc, Calverley, Peter M A, Prof

“…Summary Background Blood eosinophil counts might predict response to inhaled corticosteroids (ICS) in patients with chronic obstructive pulmonary disease…”
Get full text

The Prevention of Chronic Obstructive Pulmonary Disease Exacerbations by Salmeterol/Fluticasone Propionate or Tiotropium Bromide by Wedzicha, Jadwiga A, Calverley, Peter M. A, Seemungal, Terence A, Hagan, Gerry, Ansari, Zainab, Stockley, Robert A, INSPIRE Investigators

“…Exacerbations are key drivers of morbidity and mortality in chronic obstructive pulmonary disease (COPD). We compared the relative efficacy of the long-acting…”
Get full text

An Official American Thoracic Society Statement: Update on the Mechanisms, Assessment, and Management of Dyspnea by PARSHALL, Mark B, SCHWARTZSTEIN, Richard M, MAHLER, Donald A, MEEK, Paula M, O'DONNELL, Denis E, ADAMS, Lewis, BANZETT, Robert B, MANNING, Harold L, BOURBEAU, Jean, CALVERLEY, Peter M, GIFT, Audrey G, HARVER, Andrew, LAREAU, Suzanne C

“…Dyspnea is a common, distressing symptom of cardiopulmonary and neuromuscular diseases. Since the ATS published a consensus statement on dyspnea in 1999, there…”
Get full text

Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease by Calverley, Peter M.A, Anderson, Julie A, Celli, Bartolome, Ferguson, Gary T, Jenkins, Christine, Jones, Paul W, Yates, Julie C, Vestbo, Jørgen

“…This trial involving more than 6000 patients with chronic obstructive pulmonary disease (COPD) compared the effects on all-cause mortality of treatment with an…”
Get full text

Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort by AGUSTI, Alvar, EDWARDS, Lisa D, CRIM, Courtney, MILLER, Bruce E, COXSON, Harvey O, YATES, Julie C, TAL-SINGER, Ruth, VESTBO, Jørgen, CELLI, Bartolomé, MACNEE, William, CALVERLEY, Peter M. A, MÜLLEROVA, Hana, LOMAS, David A, WOUTERS, Emiel, BAKKE, Per, RENNARD, Steve

“…The 2011 Global Initiative for Chronic Obstructive Lung Disease (GOLD) classifies patients with chronic obstructive pulmonary disease (COPD) into four groups…”
Get full text

Blood eosinophils as a biomarker of future COPD exacerbation risk: pooled data from 11 clinical trials by Singh, Dave, Wedzicha, Jadwiga A, Siddiqui, Salman, de la Hoz, Alberto, Xue, Wenqiong, Magnussen, Helgo, Miravitlles, Marc, Chalmers, James D, Calverley, Peter M A

“…Chronic obstructive pulmonary disease (COPD) is characterised by progressive airflow limitation and chronic inflammation. Predicting exacerbations of COPD,…”
Get full text

A randomised, placebo-controlled trial of anti-interleukin-1 receptor 1 monoclonal antibody MEDI8968 in chronic obstructive pulmonary disease by Calverley, Peter M A, Sethi, Sanjay, Dawson, Michelle, Ward, Christine K, Finch, Donna K, Penney, Mark, Newbold, Paul, van der Merwe, René

“…Interleukin-1 receptor 1 (IL-1R1) inhibition is a potential strategy for treating patients with chronic obstructive pulmonary disease (COPD). MEDI8968, a fully…”
Get full text

Spirometric changes during exacerbations of COPD: a post hoc analysis of the WISDOM trial by Watz, Henrik, Tetzlaff, Kay, Magnussen, Helgo, Mueller, Achim, Rodriguez-Roisin, Roberto, Wouters, Emiel F M, Vogelmeier, Claus, Calverley, Peter M A

“…Exacerbations of chronic obstructive pulmonary disease (COPD) are associated with loss of lung function and poor outcomes for patients. However, there are…”
Get full text

Six-Minute-Walk Test in Chronic Obstructive Pulmonary Disease: Minimal Clinically Important Difference for Death or Hospitalization by POLKEY, Michael I, SPRUIT, Martijn A, COXSON, Harvey O, LAMAS, David A, MACNEE, William, RENNARD, Stephen, SILVERMAN, Edwin K, MILLER, Bruce E, CRIM, Courtney, YATES, Julie, WOUTERS, Emiel F. M, CELLI, Bartolome, EDWARDS, Lisa D, WATKINS, Michael L, PINTO-PLATA, Victor, VESTBO, Jørgen, CALVERLEY, Peter M. A, TAL-SINGER, Ruth, AGUSTI, Alvar, BAKKE, Per S

“…Outcomes other than spirometry are required to assess nonbronchodilator therapies for chronic obstructive pulmonary disease. Estimates of the minimal…”
Get full text

Effect of Pharmacotherapy on Rate of Decline of Lung Function in Chronic Obstructive Pulmonary Disease: Results from the TORCH Study by Celli, Bartolome R, Thomas, Nicola E, Anderson, Julie A, Ferguson, Gary T, Jenkins, Christine R, Jones, Paul W, Vestbo, Jorgen, Knobil, Katharine, Yates, Julie C, Calverley, Peter M. A

“…Chronic obstructive pulmonary disease (COPD) is characterized by an accelerated decline in lung function. No drug has been shown conclusively to reduce this…”
Get full text

Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD by Rennard, Stephen I, Calverley, Peter M A, Goehring, Udo M, Bredenbröker, Dirk, Martinez, Fernando J

“…As chronic obstructive pulmonary disease (COPD) is a heterogeneous disease it is unlikely that all patients will benefit equally from a given therapy…”
Get full text